论文部分内容阅读
目的探讨新辅助治疗对ⅠB2至ⅡA期宫颈癌患者近期疗效及预后的影响。方法选取2011年1月至2016年1月间新疆医科大学第二附属医院收治的100例ⅠB2期至ⅡA期宫颈癌患者进行回顾性分析,根据不同的治疗方法分为3组,采用新辅助腔内放疗的33例患者为放疗组,采用新辅助静脉化疗的33例患者为化疗组,采用新辅助静脉化疗联合腔内放疗的34例患者为联合组,辅助治疗共进行2周。对三组患者新辅助治疗后的疗效、病理危险因素、术后辅助治疗及预后进行观察比较。结果放疗组、化疗组和联合组的临床有效率分别为48.5%、51.5%和73.5%。联合组临床有效率高于放疗组和化疗组,差异有统计学意义(P<0.05);术后联合组0个中度病理危险因素和0个高度病理危险因素的比率均高于化疗组和放疗组,在中度病理危险因素和高度病理危险因素的1个和≥2个中,联合组比率均低于放疗组和化疗组,差异有统计学意义(P<0.05)。放疗组和化疗组无明显差异,差异无统计学意义(P>0.05)。三组患者5年后生存率比较,联合组生存率高于放疗组和化疗组,差异有统计学意义(P<0.05)。放疗组和化疗组无明显差异,差异无统计学意义(P>0.05)。结论腔内放疗和静脉化疗联合的新辅助治疗方法有很好的临床效果,能改善预后,对治疗ⅠB2-ⅡA期宫颈癌具有明显效果。
Objective To investigate the effect of neoadjuvant therapy on short-term efficacy and prognosis of patients with stage ⅠB2 to ⅡA cervical cancer. Methods From January 2011 to January 2016, 100 cases of stage ⅠB2 stage ⅡA cervical cancer patients admitted to the Second Affiliated Hospital of Xinjiang Medical University were retrospectively analyzed. According to the different treatment methods, the patients were divided into three groups. The new auxiliary cavity Thirty-three patients receiving radiotherapy were radiotherapy group, 33 patients receiving neoadjuvant intravenous chemotherapy were chemotherapy group, and 34 patients receiving neoadjuvant intravenous chemotherapy combined with intracavitary radiotherapy were in combination group. Adjuvant therapy was performed for 2 weeks. Three groups of patients after neoadjuvant therapy efficacy, risk factors, postoperative adjuvant therapy and prognosis were observed and compared. Results The effective rates of radiotherapy, chemotherapy and combination therapy were 48.5%, 51.5% and 73.5% respectively. The clinical effective rate in combination group was higher than that in radiotherapy group and chemotherapy group (P <0.05). The ratio of 0 moderate pathological risk factors and 0 highly pathological risk factors in combined group was higher than that in chemotherapy group and In the radiotherapy group, the ratio of combined group was lower than that of radiotherapy group and chemotherapy group in 1 and 2 of the moderate pathological risk factors and high pathological risk factors, the difference was statistically significant (P <0.05). Radiotherapy group and chemotherapy group no significant difference, the difference was not statistically significant (P> 0.05). The survival rates of the three groups after 5 years were higher than those of the radiotherapy group and the chemotherapy group, the difference was statistically significant (P <0.05). Radiotherapy group and chemotherapy group no significant difference, the difference was not statistically significant (P> 0.05). Conclusions The neoadjuvant therapy combined with intracavitary radiotherapy and intravenous chemotherapy has a good clinical effect and can improve the prognosis. It has a significant effect on the treatment of cervical cancer ⅠB2-ⅡA.